Anstee QM - Search Results

1

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.

Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Abdelmalek MF, Ding D, Han L, Jia C, Huss RS, Chung C, Wong VW, Okanoue T, Romero-Gomez M, Muir AJ, Afdhal NH, Bosch J, Goodman Z, Harrison SA, Younossi ZM, Myers RP. Sanyal AJ, et al. Among authors: anstee qm. Hepatology. 2022 May;75(5):1235-1246. doi: 10.1002/hep.32204. Epub 2022 Feb 7. Hepatology. 2022. PMID: 34662449 Free PMC article. Clinical Trial.

2

Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis.

Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P, Thomas HC, Thursz MR, Goldin RD. Anstee QM, et al. J Hepatol. 2010 Sep;53(3):542-50. doi: 10.1016/j.jhep.2010.03.016. Epub 2010 May 26. J Hepatol. 2010. PMID: 20557969

3

The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies.

Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, Daly AK. Al-Serri A, et al. Among authors: anstee qm. J Hepatol. 2012 Feb;56(2):448-54. doi: 10.1016/j.jhep.2011.05.029. Epub 2011 Jul 12. J Hepatol. 2012. PMID: 21756849

4

Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease.

Hallsworth K, Hollingsworth KG, Thoma C, Jakovljevic D, MacGowan GA, Anstee QM, Taylor R, Day CP, Trenell MI. Hallsworth K, et al. Among authors: anstee qm. J Hepatol. 2013 Apr;58(4):757-62. doi: 10.1016/j.jhep.2012.11.015. Epub 2012 Nov 22. J Hepatol. 2013. PMID: 23178979

5

Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?

McPherson S, Anstee QM, Henderson E, Day CP, Burt AD. McPherson S, et al. Among authors: anstee qm. Eur J Gastroenterol Hepatol. 2013 Jun;25(6):652-8. doi: 10.1097/MEG.0b013e32835d72cf. Eur J Gastroenterol Hepatol. 2013. PMID: 23325287

6

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.

Anstee QM, Targher G, Day CP. Anstee QM, et al. Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44. doi: 10.1038/nrgastro.2013.41. Epub 2013 Mar 19. Nat Rev Gastroenterol Hepatol. 2013. PMID: 23507799 Review.

7

Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.

McPherson S, Henderson E, Burt AD, Day CP, Anstee QM. McPherson S, et al. Among authors: anstee qm. J Hepatol. 2014 May;60(5):1055-62. doi: 10.1016/j.jhep.2014.01.010. Epub 2014 Jan 18. J Hepatol. 2014. PMID: 24445215

8

Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, Day CP, Daly AK, Reeves HL, Anstee QM. Liu YL, et al. Among authors: anstee qm. J Hepatol. 2014 Jul;61(1):75-81. doi: 10.1016/j.jhep.2014.02.030. Epub 2014 Mar 6. J Hepatol. 2014. PMID: 24607626

9

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.

McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. McPherson S, et al. Among authors: anstee qm. J Hepatol. 2015 May;62(5):1148-55. doi: 10.1016/j.jhep.2014.11.034. Epub 2014 Dec 1. J Hepatol. 2015. PMID: 25477264 Free article.

10

TM6SF2 as a genetic risk factor for fibrosis.

Daly AK, Day CP, Liu YL, Anstee QM. Daly AK, et al. Among authors: anstee qm. Hepatology. 2015 Oct;62(4):1321. doi: 10.1002/hep.27656. Epub 2015 Jun 19. Hepatology. 2015. PMID: 25502834 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

256 results

Search Page